{
    "current_api_params": {
        "Age": "50",
        "Gender": "Female",
        "Medical Condition": "Triple-Negative Breast Cancer",
        "Location": "New York, NY",
        "Latitude": "40.7128",
        "Longitude": "-74.0060",
        "Distance": 213
    },
    "last_clinical_trials_api_url": "https://clinicaltrials.gov/api/v2/studies?format=json&query.cond=Triple-Negative+Breast+Cancer&pageSize=200&filter.overallStatus=RECRUITING|NOT_YET_RECRUITING|AVAILABLE&filter.geo=distance(40.7128,-74.0060,213)",
    "stats": {
        "number_of_trials": 43,
        "trial_names": [
            "A Study of NX-1607 in Adults With Advanced Malignancies",
            "Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)",
            "A Phase 1/2 Study of [225Ac]-FPI-1434 Injection",
            "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors",
            "A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors",
            "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
            "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies",
            "A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",
            "A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers",
            "Leflunomide in Previously Treated Metastatic Triple Negative Cancers",
            "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",
            "Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer",
            "A Study of LY4170156 in Participants With Selected Advanced Solid Tumors",
            "A Study of Pembrolizumab and Cryoablation in People With Breast Cancer",
            "A Study of XMT-1660 in Participants With Solid Tumors",
            "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
            "A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer",
            "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
            "A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.",
            "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer",
            "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400",
            "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)",
            "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)",
            "Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease",
            "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors",
            "A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer",
            "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors",
            "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
            "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer",
            "A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer",
            "Comparison of the Breast Tumor Microenvironment",
            "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
            "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression",
            "A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)",
            "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors",
            "Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab",
            "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer",
            "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)",
            "A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer",
            "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)",
            "A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7",
            "A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer",
            "A Study to Investigate LYL797 in Adults With Solid Tumors"
        ],
        "nct_numbers": "NCT05107674, NCT04443348, NCT03746431, NCT03821935, NCT05453825, NCT05382286, NCT04561362, NCT05852691, NCT05544929, NCT03709446, NCT03606967, NCT02977468, NCT06400472, NCT06246968, NCT05377996, NCT05585034, NCT06099769, NCT04225117, NCT05230186, NCT02926690, NCT06084481, NCT05629585, NCT03401385, NCT03808337, NCT06238479, NCT06103864, NCT05252390, NCT01042379, NCT06112379, NCT04683679, NCT03165487, NCT05382299, NCT04180371, NCT05809752, NCT04895709, NCT05812807, NCT05902988, NCT03504488, NCT05570253, NCT05633654, NCT05958199, NCT05203445, NCT05274451"
    },
    "API_response_evaluation": "No trials"
}